Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.27 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tomivosertib | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1489
Sealed predictions
- MKNK2 in dopamine neurons, braak-0.28 (p 0.459) → -0.30 (p 0.428)receipt 1496
Swarm cases
receipt 1496: MKNK2 in dopamine neurons, braak
- power
- full sample -0.29 (p 0.250, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.23 (p 0.355, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.389, n 18). could be the mix.
- skeptic
- leave-one-out range -0.40 to -0.19, sign flips 0; without severely affected donors -0.29 (p 0.250, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MKNK2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts